Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath

RecruitingOBSERVATIONAL
Enrollment

10,000

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

June 30, 2027

Conditions
Lung CancerLung InfectionCOPDBronchitisPulmonary FibrosisPulmonary EmbolismPulmonary Arterial HypertensionPulmonary TuberculosisPulmonary AbscessEmphysemaLung InjuryCystic Fibrosis of the LungBronchial AsthmaBronchiectasisInterstitial Lung DiseasePreserved Ratio Impaired Spirometry
Interventions
OTHER

Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system

Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID

Trial Locations (1)

510140

RECRUITING

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The First Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

First People's Hospital of Foshan

OTHER

collaborator

Sichuan Cancer Hospital and Research Institute

OTHER

collaborator

Liwan District Central Hospital

UNKNOWN

collaborator

Shanghai Chest Hospital

OTHER

collaborator

Peking Union Medical College Hospital

OTHER

collaborator

Guangzhou Development Zone Hospital

UNKNOWN

collaborator

Huangpu District Hongshan Street Community Health Service Center

UNKNOWN

collaborator

Huangpu District Chinese Medicine Hospital

UNKNOWN

collaborator

Fifth Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

Huangpu District Jiufo Street Community Health Service Center

UNKNOWN

collaborator

Huangpu District Xinlong Town Central Hospital

UNKNOWN

collaborator

Huangpu District Yonghe Street Community Health Service Center

UNKNOWN

collaborator

Huangpu District Lianhe Street Second Community Health Service Center

UNKNOWN

lead

ChromX Health

INDUSTRY